Engineered viral vectors (adeno, vaccinia/MVA, lentivirus, AAV) that deliver neoantigen payloads — including Nouscom's and Transgene's programs.
A Nature study shows that oncolytic adenovirus delivery of neoantigens can sensitize low-mutation tumors to anti-PD-1 therapy and prevent metastasis. This offers a potential solution for 'cold' tumors with low neoantigen burden, leveraging viral vectors to enhance antigen presentation and immune infiltration.
Interim results from a Phase 1 trial of an individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine show activity in advanced metastatic solid tumors. This highlights the diversification of delivery vectors beyond standard mRNA, potentially offering improved immunogenicity or manufacturing advantages.
Centre Georges Francois Leclerc is initiating a Phase I study of ODI-2001, a personalized DNA neoantigen vaccine combined with a Modified Vaccinia Ankara adjuvant and ipilimumab. The trial targets metastatic or locally advanced colon and pancreatic cancers, starting with dose escalation to determine the maximum tolerated dose.